Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Warnings about the housing market are growing more dire. It points to that dreaded R word... Recession.
Housing Market News
Toldya the BLS is Deep State and not credibleMentally disabled 86TintaNoitx2024 shares more ridiculous propaganda from its Xitter feed.
It needs to find a better source for its “thoughts”.
Toldya the BLS is Deep State and not credible
Cause they are the source of the stat
Today’s surprise headline from the Wall Street Journal. Surprising because Taco has more than quadrupled the average US tariff rate since “Liberation Day.”
The Global Economy Is Powering Through a Historic Increase in Tariffs
Trade, production, growth and other global economic vitals are proving resilient almost four months after President Trump’s ‘Liberation Day’ tariffs
Trade volumes are buoyant, stock markets on both sides of the Atlantic have rebounded to record highs and growth forecasts from Europe to Asia are being raised.
Investment, manufacturing employment, spending and overall activity all held up globally, according to Goldman Sachs.
General Motors' second-quarter core profit fell 32% to $3 billion on Tuesday, as the automaker continued to confront challenging tariff policies, which it said sapped $1.1 billion from the results.
The largest U.S. automaker by sales said it expects the tariff impact to worsen in the third quarter and stuck to a previous estimate that trade headwinds threaten to hit the bottom line by $4 billion to $5 billion.
AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
no prior ACTUAL $$ INVESTMENT in teh US past 20 yrs except under Trump
AstraZeneca has made significant investments in the United States over the past 20 years, particularly in recent years. Here's a breakdown of their investments:
Major Investment Announcements:
Other Investments and Activities:
- $50 Billion Investment (Announced July 2025):AstraZeneca plans to invest a massive $50 billion in the US by 2030, with a focus on manufacturing and research and development (R&D). This includes:
- New Manufacturing Facility in Virginia: A multi-billion dollar facility for producing drug substances, specifically for chronic diseases and weight loss treatments. This will be AstraZeneca's largest single manufacturing investment globally.
- Expansion of R&D Capabilities: Expanding existing R&D facilities in Gaithersburg, Maryland, and establishing a new R&D center in Cambridge, Massachusetts.
- New Cell Therapy Manufacturing Facilities: Developing facilities in Rockville, Maryland, and Tarzana, California.
- Upgrades to Existing Manufacturing Sites: Expanding continuous manufacturing in Mount Vernon, Indiana, and specialty manufacturing in Coppell, Texas.
- New Clinical Trial Supply Sites: Creating new locations to support clinical trials.
- $3.5 Billion Investment (Announced November 2024): This earlier investment focused on expanding an R&D center in Cambridge, Massachusetts, developing a biologics manufacturing facility in Maryland, and enhancing specialty manufacturing capabilities in Texas.
Context for the Investments:
- Acquisitions: In 2007, AstraZeneca acquired Arrow Therapeutics and MedImmune, strengthening their antiviral and biologics pipeline. In 1994 and 1997, before the past 20 years but important for historical context, Zeneca (pre-merger) acquired Salick Health Care, increasing its focus on oncology.
- AI Partnerships: AstraZeneca has actively partnered with AI development companies and utilized AI platforms to discover and develop new drug targets, particularly in oncology and neurodegenerative diseases.
- Academic and Research Collaborations: AstraZeneca has engaged in partnerships with academic institutions, such as the Stanford Center for Clinical Research and the Yale-AstraZeneca Oncology Alliance, to advance research and address health challenges.
- Population Screening Initiatives: Working with organizations like the Greenbaum Cancer Center at the University of Maryland Cancer Hospitals to utilize AI for population screening.
- Clinical Trial Infrastructure: Partnering to expand clinical trial access and awareness, such as through the AIRE Mobile Unit program with IQVIA.
- These investments reflect the United States being AstraZeneca's largest market.
- They aim to strengthen the US supply chain and reduce reliance on foreign-made pharmaceuticals, particularly in response to potential tariffs on drug imports.
- The investments are expected to create numerous jobs and contribute significantly to the US economy.
But you copied and pasted this blurb that says it made significant investments in the past twenty years. I take it the second statement, from the manufacturer's spin, is more accurate than your first one about ONLY under the felon?no prior ACTUAL $$ INVESTMENT in teh US past 20 yrs except under Trump
AstraZeneca has made significant investments in the United States over the past 20 years, particularly in recent years. Here's a breakdown of their investments:
Major Investment Announcements:
Other Investments and Activities:
- $50 Billion Investment (Announced July 2025):AstraZeneca plans to invest a massive $50 billion in the US by 2030, with a focus on manufacturing and research and development (R&D). This includes:
- New Manufacturing Facility in Virginia: A multi-billion dollar facility for producing drug substances, specifically for chronic diseases and weight loss treatments. This will be AstraZeneca's largest single manufacturing investment globally.
- Expansion of R&D Capabilities: Expanding existing R&D facilities in Gaithersburg, Maryland, and establishing a new R&D center in Cambridge, Massachusetts.
- New Cell Therapy Manufacturing Facilities: Developing facilities in Rockville, Maryland, and Tarzana, California.
- Upgrades to Existing Manufacturing Sites: Expanding continuous manufacturing in Mount Vernon, Indiana, and specialty manufacturing in Coppell, Texas.
- New Clinical Trial Supply Sites: Creating new locations to support clinical trials.
- $3.5 Billion Investment (Announced November 2024): This earlier investment focused on expanding an R&D center in Cambridge, Massachusetts, developing a biologics manufacturing facility in Maryland, and enhancing specialty manufacturing capabilities in Texas.
Context for the Investments:
- Acquisitions: In 2007, AstraZeneca acquired Arrow Therapeutics and MedImmune, strengthening their antiviral and biologics pipeline. In 1994 and 1997, before the past 20 years but important for historical context, Zeneca (pre-merger) acquired Salick Health Care, increasing its focus on oncology.
- AI Partnerships: AstraZeneca has actively partnered with AI development companies and utilized AI platforms to discover and develop new drug targets, particularly in oncology and neurodegenerative diseases.
- Academic and Research Collaborations: AstraZeneca has engaged in partnerships with academic institutions, such as the Stanford Center for Clinical Research and the Yale-AstraZeneca Oncology Alliance, to advance research and address health challenges.
- Population Screening Initiatives: Working with organizations like the Greenbaum Cancer Center at the University of Maryland Cancer Hospitals to utilize AI for population screening.
- Clinical Trial Infrastructure: Partnering to expand clinical trial access and awareness, such as through the AIRE Mobile Unit program with IQVIA.
- These investments reflect the United States being AstraZeneca's largest market.
- They aim to strengthen the US supply chain and reduce reliance on foreign-made pharmaceuticals, particularly in response to potential tariffs on drug imports.
- The investments are expected to create numerous jobs and contribute significantly to the US economy.
YOU ARENT VERY BRIGHT!But you copied and pasted this blurb that says it made significant investments in the past twenty years. I take it the second statement, from the manufacturer's spin, is more accurate than your first one about ONLY under the felon?
You can't prop up Trump by citing CHAT.gpt info that contradicts your own words, Bubba.
How Trump’s Economy Continues To Defy The ‘Experts’ And Shock The ‘Panicans’
For the "experts," the rapid pace of the administration's economic agenda has been shocking. For President Trump, this was all a part of the plan
MajorRewrite should change her name to Private Revision.
Observant enough to spot your false claim and failure to source your references. It doesn't take much to point out glaring falsehoods. I've had lots of practice spotting those in Trump's daily dosages.YOU ARENT (sic) VERY BRIGHT!

Your numbers are pretty much sound, as far as they go. However, cherry-picking the positives can shade those that are not doing so well. I picked your friend CHAT.gpt's brain, and it coughed up this for your conversation:How Trump’s Economy Continues To Defy The ‘Experts’ And Shock The ‘Panicans’
For the "experts," the rapid pace of the administration's economic agenda has been shocking. For President Trump, this was all a part of the plan.
By Zach Jewell
•
Jul 21, 2025 DailyWire.com
https://dw-wp-production.imgix.net/2025/07/Donald-Trump-10-scaled-e1753115678636.jpg?ar=16%3A9&auto=compress&crop=faces&cs=origin&fit=crop&w=1035?ar=16:9&fit=crop&crop=faces&fm=webpAFP via Getty Images
In the first six months of President Donald Trump’s second term, one major theme has defined Trump’s economic record thus far: success that surprises the people who are paid to predict it.
It hasn’t been surprising for the president, who is carrying out his promise to revamp American manufacturing and boost American jobs, mainly by imposing unprecedented tariffs on nearly every country in the world. And it comes as economists who predicted large-scale inflation and market downturn over Trump’s bold economic agenda keep seeing economic metrics come across their desks showing the opposite.
Earlier this year, Americans were told to brace their wallets for rising inflation and prepare for a recession caused by Trump’s major tariffs, especially those levied on America’s biggest trading partners, China, Canada, and Mexico. In May, Goldman Sachs analysts said core goods inflation could hit 6.3% by the end of the year while consumer prices would spike 3.7% by early 2026, according to CNN.
The latest numbers on the U.S. economy fly in the face of the naysayers, branded by Trump as “panicans.” Late last week, the U.S. Census Bureau reported that June retail sales were up 0.6% from May and up 3.5% from last year. Food service and drinks sales jumped 6.6% from June 2024. Those numbers were, of course, better than what economists had predicted — a phrase that has become a monthly tradition since Trump stepped back into the White House
More here: https://www.dailywire.com/news/how-...es-to-defy-the-experts-and-shock-the-panicans
MajorRewrite should change her name to Private Revision.